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The brindledmouse is an accuratemodel of the fatal humanX-linked copper deficiency disorder,Menkes disease.Males carrying themutant allele
of the Menkes gene orthologue Atp7a die in the second week of life. To determine whether the genetic defect in the brindled mice could be corrected
by expression of the humanMenkes gene, male transgenic mice expressing ATP7A from the chickenβ-actin composite promoter (CAG) were mated
with female carriers of the brindled mutation (Atp7aMo-br). Mutant males carrying the transgene survived and were fertile but the copper defect was
not completely corrected. Unexpectedly males corrected with one transgenic line (T25#5) were mottled and resembled carrier females, this effect
appeared to be caused by mosaic expression of the transgene. In contrast, males corrected with another line (T22#2) had agouti coats. Copper
concentrations in tissues of the rescued mutants also resembled those of the heterozygous females, with high levels in kidney (84.6±4.9 μg/g in
corrected males vs. 137.0±44.3 μg/g in heterozygotes) and small intestine (15.6±2.5 μg/g in corrected males vs. 15.7±2.8 μg/g in heterozygotes).
The results show that the Menkes defect in mice is corrected by the human Menkes gene and that adequate correction is obtained even when the
transgene expression does not match that of the endogenous gene.
© 2006 Elsevier B.V. All rights reserved.Keywords: Gene correction; Menkes disease; Copper-transporting ATPase; Menkes protein; Brindled mutant mouse; CAG-promoter1. Introduction
The mottled mice are an allelic series of mouse mutants that
are due to mutations in the murine orthologue of the X-linked
Menkes genes (Atp7a) [1,2]. The mutant males exhibit a wide
range of phenotypes ranging from prenatal lethality to mild
symptoms such as a grey coat [3]. The carrier females are
readily identified because they have a mottled coat due to the
random X-inactivation while the unaffected mice have an agouti
coat [4]. As with the human disorder Menkes disease, the
various defects in the mice are attributable to copper deficiency
affecting a range of copper-dependent enzymes [5]. The
affected gene encodes a copper transporting ATPase (Atp7a),
which supplies copper to secreted cuproenzymes and also
effluxes copper from the cell [6]. This copper transporter has an
important role in transporting copper across the placenta, and
mutant fetuses are severely copper deficient as a result, but the⁎ Corresponding author. Fax: +61 3 92517328.
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doi:10.1016/j.bbadis.2005.12.011placenta accumulates copper [7]. The closest mottled mutant to
Menkes disease is the brindled mouse, mutant males carrying
the brindled allele Atp7aMo-br survive until about 15 days after
birth, and have a markedly hypopigmented coat and curly
whiskers due to copper deficiency [4]. The mutation in Atp7a in
the brindled mouse was found to be an in-frame deletion of 6
nucleotides, resulting in the loss of two highly conserved amino
acids [8]. The brindled mutant mouse can be rescued by copper
treatment provided this occurs before 10 days postnatal [9].
These mice have been used to investigate the treatment of
Menkes disease, however, in contrast with the success with the
brindled mice, the treatment of human patients with copper salts
or even with copper histidine has not proven to be very
successful, with only a handful of successfully treated patients
being reported [10].
The wide range of defects in the mottled mice suggests that
Atp7a is involved in various aspects of copper physiology in
addition to placental transport. These include uptake of copper
across the small intestine and transport of copper across the
blood brain barrier [11]. The fact that copper accumulates in the
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resorption of copper from the urine. Copper is absorbed into the
proximal tubules, but because of the lack of Atp7a, the copper is
trapped in cells and accumulates in the organ [12]. The Menkes
protein is not expressed in hepatocytes [13], where the
important copper homeostatic mechanism of biliary copper
excretion is carried out by the closely related protein, ATP7B
which is defective in the copper toxicity condition, Wilson
disease [14].
To investigate the possibility of gene correction of Menkes
disease we report here the use of transgenic mice that express
the human Menkes protein (ATP7A) to demonstrate that the
human Menkes gene (ATP7A) allows survival of the brindled
mutant, the mouse model of Menkes disease. Despite
expression patterns that do not entirely match the endogenous
gene, the corrected mice are fertile and survive for more than 2
years, but the phenotype of the mutant males corrected with the
transgenic line T25#5 resembled that of the heterozygote
females.
2. Materials and methods
2.1. Animals
All animal studies were approved by Deakin University Animal Welfare
Committee (A1/1999 and A20/A2001). Animals were housed under constant
conditions with a 12-h light and 12-h dark cycle, and given deionised water and
standard lab chow (Barastoc, Ridley AgriProducts, Australia) ad libitum. The
transgenic mice were maintained in the C57BL/6 background, and the brindled
allele of the X-linked mottled mutants, Atp7aMo-br in our laboratory is
maintained on a C3H/CBA background.
2.2. Screening of transgenic lines
Mice were genotyped by PCR of tail DNA using the following primer set:
sense oligonucleotide Y2H7 (5′-TCTCTCTTCCTTAAACTTTAC)
corresponding to the 3′ end sequence of ATP7A and the antisense
oligonucleotide SP6 (5′-ATTTAGGTGACACTATAG) from the vector. PCR
conditions were: 95 °C for 3 min for one cycle, then 30 cycles of: 94 °C for 30 s,
56 °C for 1 min, 72 °C for 1 min. Animals shown to be transgenic were
subsequently mated to wild-type C57BL/6 mice. Transgenic lines were
maintained as heterozygotes.
2.3. Rescue of the brindled males
Transgenic male mice were mated with females carrying the Atp7aMo-br/+ X-
linked mottled allele. Pups were screened for presence of the transgene by PCR
using the primers Y2H7 and SP6 as described previously and the Atp7aMo-br
mutation was detected by PCR [8]. In brief, sense oligonucleotides MMNK22
(5′-GGCAAAACCTCCGAGGCAAAG) specific for the mutant allele or
MMNK23 (5′-CAAAACCTCCGAGGCTCTTGC) specific for the wild type
allele and antisense oligonucleotide MMNK24L (5′-AGGAGGAGATTTTCA-
GAGTTCAG)were used to amplify products of 83 bp and 87 bp, respectively, in
separate reaction tubes. PCR conditions were: 96 °C for 4 min, 63 °C for 1 min,
72 °C for 1min for two cycles followed by 96 °C for 1min, 63 °C for 1min, 72 °C
for 30 s for 35 cycles. The productswere analysed on 4% agarose 3:1™HRBgels
(Amresco, Solon, Ohio, USA) and detected by staining with ethidium bromide.
2.4. Antibodies
Affinity-purified ATP7A antibody (R17-BX) has been described [15].
Polyclonal anti-calnexin antibody (1:500) was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).2.5. Western blot analysis
Protein extracts were prepared by homogenisation of lung, heart, liver,
kidney, small intestine, brain and spleen in 140 mM Tris–HCl (pH 6.8),
6% SDS, 22.4% glycerol and one Mini-EDTA free protease inhibitor
tablets (Roche Diagnostics GmbH, Mannheim, Germany) per 10 ml of
homogenisation buffer. The protein concentration was determined by BCA
method (Pierce, Rockford, IL, USA). Samples containing 40 μg of
protein were separated using 7.5% SDS/PAGE, transferred to Hybond-C
(Amersham Biosciences, Bucks, UK) and probed with the R17-BX
antibody. Protein bands were detected by donkey anti-sheep/goat
horseradish peroxidase-coupled secondary antibody (Chemicon, Melbourne,
Vic, Australia) using Lumilight Western Blotting Substrate (Roche
Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's
instructions.
2.6. Immunohistochemical analysis
Brain, kidney, heart and lung were immersion-fixed in 4% PFA in PBS for
5–24 h at 4 °C, embedded in paraffin and sectioned at 4 μm on a Microm
HM330 microtome (Walldorf, Germany). Small intestine and liver were
embedded in OCTcompound (Tissue-Tek, Sakura Finetek, Torrance, CA, USA)
on dry ice and sectioned on a Leica CM1850 cryostat (Leica, Nussloch,
Germany) at 4 μm. The sections were air dried for 24 h at room temperature and
fixed in 4% PFA in PBS. All tissue sections were treated with 3% H2O2 for 10
min to inactivate endogenous peroxidase and blocked in 1% normal rabbit
serum for 1 h at room temperature. The sections were then incubated with R17-
BX antibody diluted 1:2000 in PBS (1:1000 on liver sections) for 1h at room
temperature or 24h at 4 °C. Binding of the primary antibody was visualized with
the Vectastain ABC Kit and Nova Red as the chromogen (Vector Laboratories,
Burlingame, CA, USA). Sections were counterstained with Harris's heamatox-
ylin (Amber Scientific, Belmont, WA, Australia) and mounted with DXT
(Chem-Supply, Gillman, SA, Australia).
2.7. Real time quantitative polymerase chain reaction
Total RNA was isolated using the Qiagen RNeasy Mini Kit according to
the manufacturer's instructions (Qiagen, Clifton Hill, Vic, Australia). cDNA
was generated from 5 μg RNA using StrataScript® reverse transcriptase
(Stratagene, East Kew, Vic, Australia) following the manufacturer's instruc-
tions. The specific primers for ATP7A were (5′-GCTACCTTGTCAGACAC-
GAATGAG, and 5′-TCTTGAACTGGTGTCATCCCTTT) and for Atp7a
were (5′-AAACCTTGCGAGAAGCAATTG, and 5′-GGGCAAAA-
GAGGTGTTTCCA). Real time PCR was performed in triplicate on 20 ng
cDNA (RNA content prior to reverse transcription) using the AB 7500 Real
Time PCR System (Applied Biosystems, Scoresby, Vic, Australia) coupled
with SYBR Green technology (Applied Biosystems, Scoresby, Vic, Australia).
The threshold cycle value (Ct), defined as the cycle number when
fluorescence level exceeds the threshold value was determined using the
AB 7500 software. The fold change relative to Atp7a in the corrected mutant
male was calculated using the following equation: 2ΔCt where ΔCt=mean Ct
of endogenous Atp7a−mean Ct of ATP7A. Values represent mean fold
change±standard deviation.
2.8. Determination of tissue copper concentration
Tissues were analysed for trace metals by flame atomic absorption
spectrometry, using a Varian GTA 100 spectrophotometer (Mulgrave, Vic,
Australia).
2.9. Statistical analysis
All values are expressed as means±S.D., unless otherwise indicated.
Mann–Whitney tests or Student's t-tests were used to assess statistical
differences between two given genotypes. A P value b0.05 was considered
significant.
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3.1. Correction of the Menkes defect in the mottled mouse
mutant
We used two lines of transgenic mice (T25#5 and T22#2)
expressing the human Menkes gene to correct the brindled
mutants. The generation and characterization of the lines is
described elsewhere [15]. In these lines ATP7A is regulated by
the chicken β-actin promoter (CAG) and the transgene was
found to be widely expressed with some differences in
expression pattern between the lines. To introduce the CAG-
ATP7A transgene into the mutant brindled males, T25#5 or
T22#2 transgenic male mice were mated with non-transgenic
females heterozygous for the Atp7aMo-br X-linked mottled
allele. Pups were genotyped by PCR of tail DNA for their
transgenic status and for the brindled mutation using allele-
specific oligonucleotides, as described in Materials and
methods. Amplification of the mutant allele generated a
83bp PCR product compared to a 87bp fragment from the
wild type allele as previously described [8]. Fig. 1A shows the
PCR results from the four possible Atp7a genotypes generated
from such mating (transgene status is not shown). Out of the
total number of 148 pups genotyped at d9 postnatal, 19 were
found to be uncorrected brindled mutants and 18 were found to
be corrected mutants, the predicted number being 18.5. The
uncorrected mutant males were hypopigmented (Fig. 2A) and
died between 14 and 20 days. The transgenes permitted
survival of the mutant but surprisingly the T25#5 corrected
mutants (Fig. 2C and D) had a mottled coat similar to the
heterozygous females (Fig. 2B). Apart from the mottling of theFig. 1. Characterization of the corrected mutant mice. (A) PCR detection of the
brindled mutation in tail DNA from the progeny of transgenic male mice mated
with non-transgenic females heterozygous for the Atp7aMo-br X-linked mottled
allele. Primers MMNK22 and MMNK24L detect the mutant allele (M) and
primers MMNK23 and MMNK24L detect the wild type allele (W). (B) Growth
curves of corrected mutant and normal male mice. Measurements represent the
average weight of three corrected mutant mice (dashed line) and two normal
male littermates (solid line). Error bars indicate standard deviation.coat of the T25#5 corrected mutant males, corrected mutant
males appear in good health and have survived for more than 2
years. Their growth rate was similar to the normal male
littermates (Fig. 1B) and no significant difference was found
between the weight of the corrected mutant males and their
normal littermates at d60 postnatal (Student's t-test). To
establish the fertility of the corrected mutant males and
demonstrate transmission of the mutant allele the corrected
males were mated with C57Bl/6 females and pups were
genotyped as described in Materials and methods. As expected
from X-linked inheritance patterns, all female pups were
heterozygote for the brindled allele and no brindled males were
produced. Out of a total number of 59 progeny, 12 were
Atp7aMo-br/+, Tg+; 15 were Atp7aMo-br/+, Tg−; 11 were
Atp7a+/y, Tg+ and 21 were Atp7a+/y, Tg−. Most of the work
described in this paper is on the T25#5 corrected males, as this
line was characterized first. Subsequently, we investigated the
correction by a different transgenic line, T22#2. Interestingly,
T22#2 corrected males had an agouti coat colour similar to
their wild type littermates (Fig. 2E and F) but otherwise were
similar in health, growth rate and longevity compared with the
T25#5 corrected males. The corrected mutant males of both
lines had straight whiskers (note Fig. 2C–F) contrasting with
the curly whiskers of the uncorrected mutant (Fig. 2A), which
are caused by copper deficiency.
3.2. Transgene expression in the corrected mutant males
The expression of the ATP7A protein and ATP7A mRNA
levels in a range of tissues from T25#5 corrected mutant males
were determined by Western blot analysis (Fig. 3A) using an
affinity purified anti-ATP7A antibody R17-BX [15] and real
time PCR (Fig. 3B). The R17-BX antibody could detect the
mouse Atp7a as well as the human protein, however, the
sensitivity of the antibody was not sufficient to detect the
endogenous protein in most tissues of the non-transgenic
animals. Bands at a similar size to ATP7A (178 kDa) were seen
in samples from the lung, kidney, brain and spleen with highest
levels in kidney (Fig. 3A top panel). The human protein,
ATP7Awas expressed in a wide range of tissues of the corrected
mutant male, albeit to varying extents and migrated in a position
consistent with the expected size of 178 kDa (Fig. 3A bottom
panel) [16]. A strong signal was observed in heart and lower
levels of expression were seen in small intestine, brain, lung,
spleen and kidney. Expression in the liver was very low, the
band present at a lower Mr in Fig. 3A is an artifact due to the
presence of a major liver protein at that position in the gel and is
present in both the non-transgenic and transgenic livers.
Calnexin, the loading control could not be detected in non-
transgenic small intestine, most likely due to degradation in this
particular sample, since we routinely are able to visualize it.
Nevertheless, we have been unable to detect endogenous Atp7a
in small intestine when the calnexin band is visible. Since
endogenous Atp7a is not detected in all tissues tested we could
not determine the expression levels of ATP7A relative to the
endogenous protein. To estimate the relative levels of transgene
expression to the endogenous Atp7a gene expression, mRNA
Fig. 2. Appearance of corrected mutant mice. (A) Uncorrected mutant mouse at 12 days of age. (B) Heterozygote female. (C) T25#5 corrected mutant male mouse at
105 days of age. (D) Another T25#5 corrected mutant male mouse at 78 days of age (left) compared to a normal male littermate (right). (E) T22#2 corrected mutant
male mouse at 186 days of age. (F) Another T22#2 corrected mutant male mouse at 135 days of age (left) compared to a normal male littermate (right).
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quantitative PCR (Fig. 3B) on tissue samples from the same
corrected mutant male presented in Fig. 3A. ATP7A mRNA
expression levels relative to Atp7a levels were markedly
increased in heart (244 fold), small intestine (38 fold), brain
(11 fold), lung (7 fold), kidney (3 fold) and spleen (2 fold).
Lower expression levels were measured in liver (1.7 fold)
consistent with the Western blot results.
The cellular distribution of ATP7A in various organs was
determined by immunohistochemistry using the R17-BX
antibody. Endogenous Atp7a was undetectable in non-trans-
genic mice under the conditions used (data not shown). The
transgene was expressed in a mosaic pattern in most tissues
examined (Fig. 4). In the lung ATP7A was detected in smooth
muscle of pulmonary vessels, but not in the parenchyma (Fig.
4A). In the heart the transgene was expressed in cardiac muscle
(Fig. 4B). In the liver, we found expression of the transgene in
clusters of hepatocytes (Fig. 4C), however, the majority of
hepatocytes did not appear to express ATP7A. Interestingly the
protein appeared to be at the plasma membrane rather than in an
intracellular location as was seen in most other cell types. In the
small intestine the transgene was expressed in the perinuclearregion on the apical side of the enterocytes (Fig. 4D) consistent
with the TGN localization in these cells reported by Monty et al.
[17]. In kidney, the transgene was expressed in the macular
densa of the distal tubules (Fig. 4E), in tubules in the outer
cortex (Fig. 4F), as well as in the thin loops of Henle in the outer
medulla (data not shown). In the brain, we found transgene
expression in the Purkinje cell layer of the cerebellum (Fig. 4G),
in the CA1 and CA2 region of the hippocampus (Fig. 4H), the
mitral layer of olfactory bulb and in some instances in the
vascular endothelium (data not shown). Some expression was
detected in the choroid plexus but we could not detect
expression in astrocytes (data not shown).
3.3. Effect of ATP7A expression on Cu concentration in
corrected mice
Copper concentrations in the mice were determined at 12
days (Table 1) and 60 days postnatal (Table 2). Copper
concentrations in the heart of the uncorrected mutant male at
12 days of age were much lower than normal (8.8±2. μg/g vs.
24.1±9.7 μg/g) but the copper concentrations were restored to
normal levels in the heart of the corrected mutants. In the liver,
Fig. 3. Transgene expression in mouse tissues. (A) Representative Western blots
of 40 μg protein extracts from a normal male, Tg− (top panel) and a corrected
mutant male (bottom panel) mouse tissues. The R17-BX antibody detected
ATP7A (178 kDa) in lung, heart, spleen, kidney, small intestine (SI), and brain
of the corrected mutant male. Endogenous Atp7a was detected in lung, kidney,
brain and spleen. Calnexin was used as a loading control and detected using a
polyclonal antibody. (B) Gene expression of ATP7A in the same corrected
mutant male analysed by Western blot. mRNA levels were expressed relative to
endogenous Atp7a. Real time quantitative PCR data for normal male (open bars)
and corrected mutant male (dotted bars) represent mean fold change±standard
deviation in the logarithmic scale.
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typically found in mice prior to weaning [18]. The uncorrected
male mutant and the heterozygous females both had very low
copper concentrations in their livers. The presence of the
transgene in the male mutants increased the hepatic copper
concentrations by about 50%, still well below the normal
values. Interestingly the expression of ATP7A in the
heterozygous females caused a marked increase (250%) in
hepatic copper concentrations but not to the levels found in
normal animals. Both the heterozygous female and the mutant
male had very high copper concentrations in the kidney. The
expression of the transgene decreased the kidney copper
concentrations in the heterozygous female, but increased the
copper in the kidneys of the corrected males. Although ATP7A
was well expressed in the small intestine (Fig. 4B), this did not
appear to correct the elevation of copper in the small intestine
of the mutant male or heterozygous female. The brain of the
uncorrected mutant had extremely low copper concentrations
(3.3±0.1 μg/g vs. 8.9±1.4 μg/g in normal mice), this severe
copper deficiency was completely corrected by the expression
of the transgene.Copper concentrations in the tissues of the 60-day-old
animals is shown in Table 2. The uncorrected mutant males had
all died by this age. Copper concentrations in the corrected
mutants heart and liver were normal. In the kidney of the
corrected males, the copper concentrations were almost 6 fold
higher than the normal males, and were similar to the values
seen in the heterozygous females expressing the transgene; the
non-transgenic heterozygous females, however, had renal
copper concentrations approximately 9 fold higher than normal
females. The small intestine copper levels were slightly elevated
in the corrected mutant males, and again resembled the values
seen in the heterozygous females. By this age, the brain copper
concentrations of all genotypes was similar.
4. Discussion
The expression of the human Menkes protein permitted
survival of the brindled mutant males, however, the copper
concentrations were not restored to those found in the normal
male but were similar to copper concentrations in the
heterozygous females. As we found here and previously
reported [19,20], the females heterozygous for the Atp7aMo-br
allele have quite abnormal copper concentrations with pro-
nounced copper accumulation in the small intestine, kidney and
low copper concentrations in the liver similar to the values seen
in the mutant male, yet the females survive normally. The
explanation for the copper accumulation is that, as a result of
random X-inactivation, approximately 50% of cells in each
tissue are expressing the mutant allele and accumulate copper
due to defective efflux. As with cells from patients with Menkes
disease, the mutant cells take up copper but cannot efflux it,
leading to accumulation [21]. The intestinal enterocytes
expressing the normal allele of Atp7a transport copper into
the body, clearly allowing sufficient copper to reach critical
enzymes to permit normal growth and development. The low
levels of copper in the liver are an indication that supplies of
copper are limited, probably due to a combination of the
reduced intestinal transport (only 50% of cells operating
transporting copper), and a “copper sink” effect of cells
expressing the mutant allele accumulating copper. Thus, the
heterozygous female is a genetic mosaic of cells in which
copper is normally handled and cells in which copper is
accumulating, but is not transported across the transGolgi
network to cuproenzymes in the secretory pathway. This
mosaicism manifests as a mottled coat; the normally pigmented
cells have an active tyrosinase that receives copper from Atp7a,
and the hypopigmented patches represent cells containing an
inactive tyrosinase due to the mutant Atp7a.
Our data suggests that, like the heterozygous female, the
males corrected with the T25#5 transgene are a genetic mosaic
of transgene-expressing or non-expressing cells (e.g., Fig. 4).
The consequences for coat colour and tissue copper accumu-
lation are similar to that seen in the heterozygous females,
however, the exact phenotype will depend on the pattern of
transgene inactivation, which is likely to vary between lines of
mice and possibly even between individuals of the same line.
The observation that the corrected males of the T22#2 line have
Fig. 4. Immunohistochemical analysis of ATP7A in various tissues of a representative corrected mutant male mouse collected at 60 days postnatal. Tissue sections were
prepared as described in Materials and methods, and ATP7A was detected with the R17-BX antibody and immunoperoxidase staining. Endogenous Atp7a was not
detected (data not shown). ATP7A expression was detected in lung (A), heart (B), liver (C), SI (small intestine) (D), kidney (E and F), the Purkinje cell layer of the
cerebellum (G) and in the CA2 region of the hippocampus (H). Arrows indicate a typical cell expressing ATP7A. In panels B, E and F there is some background
staining due to longer development time for those sections. Scale bar=50 μm.
490 R.M. Llanos et al. / Biochimica et Biophysica Acta 1762 (2006) 485–493a normal coat suggests that the transgene in this line is
uniformly expressed in the skin, but other data has shown
mosaic expression in other tissues [15]. Mosaic expression of
transgenes is not uncommon and presumably reflects random
silencing events as was shown for the keratin 5/lacZ constructs
which express in a mosaic fashion in the epithelium of
transgenic mice [22] and may be a consequence of the
chromosomal integration site or transgene copy number [23].
We have not investigated the site of integration of the transgene
or the copy number in transgenic lines T25#5 and T22#2,
however, PCR screening for presence of the transgene suggests
that the copy number of the T22#2 line is higher than that of the
T25#5 line (not shown). Variable transgene expression has beenreported for a number of genes regulated by the CAG promoter
[24–26]. Although this property could potentially be an issue if
one is considering gene correction for Menkes disease, our
results demonstrate that even partial correction is sufficient to
achieve normal growth and development.
ATP7A expression and ATP7A mRNA levels were found to
vary widely between the tissues of the corrected mutant mice.
Expression was highest in the heart muscle cells where the
levels were over two hundred times relative to the endogenous
mRNA. In cells where the endogenous protein was detectable,
such as the kidney, relative levels were about 3 fold higher than
the endogenous gene. The high relative expression in the heart
is due to a combination of the high activity of the CAG
Table 1
Tissue copper concentration in organs of 12-day-old progeny generated from the mating of transgenic male and Atp7aMo-br female mice
Tg and description Coat
colour
Genotype Cu μg/g dry weight of mice tissue
Heart Liver Kidney SI Brain
Normal female (−) Ag Tg− Atp7a+/+ 17.2±6.6 (6) 222±81.4 (8) 16.9±7.0 (5) 20.8±8.0 (7) 11.1±3.0 (7)
Normal female (+) Ag Tg+ Atp7a+/+ 18.0±4.0 (4) 164.8±92.2 (6) 10.0±1.3 (4) 20.9±6.9 (5) 8.5±1.4 (6)
Heterozygote female (−) Br Tg− Atp7aMo-br/+ 20.4±9.1 (6) 14.9±3.6 (6) 88.2±7.7 (5) 35.5±3.6 (5) 5.9±1.4 (6)
Heterozygote female (+) Ag or Br Tg+ Atp7aMo-br/+ 13.4±5.8 (6) 52.8±13.6 (5)a 71.2±5.8a 48.8±18.6 (5)a 7.8±2.4 (5)
Normal male (−) Ag Tg− Atp7a+/y 24.1±9.7 (5) 164.5±52.4 (6) 18.5±8.1 (5) 24.4±6.9 (6) 8.9±1.4 (5)
Normal male (+) Ag Tg+ Atp7a+/y 17.1±4.6 (4) 164±70.6 (5) 19.3±5.1 (4) 14.9±2.7 (5) 10.9±2.8 (5)
Uncorrected mutant (−) Wh Tg− Atp7aMo-br/y 8.8±2.1 (4) 10.7±2.4 (7) 52.2±10.3 (6) 59.2±43.2 (7) 3.3±0.1 (5)
Corrected mutant (+) Br Tg+ Atp7aMo-br/y 21.5±8.2 (3)b 15.8±4.5 (4)c 66.0±15.6 (4)c, d 54.9±27.4 (4)c 9.3±3.5 (4)b
Results are copper concentration expressed as μg/g dry weight of tissue±standard deviation, number of observations in parentheses. SI, small intestine. Ag=normal
agouti coat, Br=mottled brindled coat, Wh=white coat. Tg− and Tg+ refer to non-transgenic and transgenic mice, respectively. Pb0.05 were found for the following
pairs:
a Heterozygote female (+) versus normal female (+).
b Corrected mutant (+) versus uncorrected mutant (−).
c Corrected mutant (+) versus normal male (+).
d Corrected mutant (+) versus heterozygote female (−).
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levels in this tissue.
The over-expression of ATP7A did not result in apparently
abnormal intracellular distribution of the protein as it was found
in regions consistent with the transGolgi network, the
established location of the Menkes protein in a normal copper
environment [27]. Elevated levels of ATP7A in cells has shown
to cause depletion of copper, due to enhanced efflux of copper
[28,29], and this effect is apparent in the trend for reduced
copper concentrations in the hearts of the transgenic animals
(Table 2) [15]. It has not been established whether this copper
depletion has any physiological consequences for the heart.
ATP7A was expressed in patches of hepatocytes in the liver
of the corrected mice, and unlike other cell types appeared
located on the plasma membrane, rather than in a region
consistent with the TGN. It is probably that this region is the
basolateral surface of the hepatocyte, as ATP7A has been shown
to traffic to the basolateral surface in polarized cells [30] and
proteins that are located on the apical surface of hepatocytes
give a characteristic discrete circular staining pattern [31,32].
Normally, hepatocytes do not express ATP7A, instead theyTable 2
Tissue copper concentration in 60-day-old progeny generated from the mating of tra
Tg and description Coat
colour
Genotype Cu μg/g dry we
Heart
Normal female (−) Ag Tg− Atp7a+/+ 19.3±2.2 (5)
Normal female (+) Ag Tg+ Atp7a+/+ 17.1±2.6 (4)
Heterozygote female (−) Br Tg− Atp7aMo-br/+ 22.1±5.0 (5)
Heterozygote female (+) Ag or Br Tg+ Atp7aMo-br/+ 17.1±3.0 (4)
Normal male (−) Ag Tg− Atp7a+/y 18.5±2.0 (5)
Normal male (+) Ag Tg+ Atp7a+/y 13.8±2.3 (7)
Corrected mutant (+) Br Tg+ Atp7aMo-br/y 15.5±2.9 (5)b
Results are copper concentration expressed as μg/g dry weight of tissue±standard de
agouti coat, Br=mottled brindled coat. No data are listed for the uncorrected mutants
following pairs:
a Heterozygote female (+) versus normal female (+).
b Corrected mutant (+) versus heterozygote female (−).
c Corrected mutant (+) versus normal male (+).express the closely related Wilson protein, ATP7B [31]. When
the copper levels in the hepatocyte are low, ATP7B is found in
the TGN, but the protein traffics to large vesicles in the vicinity
of the biliary canalicular membrane when the copper levels are
elevated leading to biliary excretion of copper [31]. Our result
suggests a physiological reason for the lack of ATP7A
expression in the liver in normal animals. If ATP7A were
normally expressed in hepatocytes it would presumably pump
copper into the sinusoidal space, and hence back into the
circulation, rather than delivering excess copper into the bile
and act in opposition to the biliary excretion role of ATP7B. It
will be of interest to explore further the physiological
consequences of this presumed reversal of copper flow in
further experiments.
Although the pattern of expression of the transgene in tissues
did not precisely match that of the reported expression patterns
of the endogenous gene [12], ATP7A was expressed in the
tissues critically important for the survival of the mutant mice.
For example, ATP7A was well expressed in the intestinal ente-
rocytes where copper accumulates in mutants when the Menkes
protein is defective [19], and this expression presumably allowsnsgenic male and Atp7aMo-br female mice
ight of mice tissue
Liver Kidney SI Brain
15.6±2.1 (4) 17.9±1.5 (5) 8.2±2.3 (5) 15.0±1.1 (5)
13.5±1.5 (4) 15.1±1.4 (4) 9.7±1.5 (4) 14.6±1.4 (4)
14.1±1.8 (5) 137.0±44.3 (4) 15.7±2.8 (5) 11.3±3.2 (5)
14.7±3.9 (5) 82.6±14.1 (5)a 14.4±1.2 (5)a 15.9±1.0 (5)
19.2±2.7 (5) 17.1±2.2 (5) 9.6±1.5 (5) 13.4±1.1 (5)
18.4±2.5 (6) 14.6±3.1 (7) 9.0±0.9 (7) 15.0±1.4 (7)
17.7±1.7 (6) b 84.6±4.9 (6)c, b 15.6±2.5 (6)c 15.3±1.9 (6)
viation, number of observations in parentheses. SI, small intestine. Ag=normal
(−) because they all died around 14–20 days of age. Pb0.05 were found for the
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shown that ATP7A in the intestinal enterocytes of the ATP7A
transgenic mice responded to increasing copper in the lumen of
the small intestine by trafficking from a perinuclear region to
vesicles in the basolateral region, presumably facilitating copper
delivery to the circulation [17]. The fact that the brain copper is
restored to normal is of critical importance for the survival of the
mice. The Menkes protein is thought to be necessary for the
transport of copper across the blood brain barrier, and in mutant
mice copper has been found to accumulate in the vascular
endothelium and astroglial cells of the mouse brain [33].
Surprisingly, we could not detect consistent expression of the
transgene in the vascular endothelial cells or astrocytes,
nevertheless we suggest that a low but undetectable amount of
ATP7A must have been present, otherwise copper would not
have been able to reach the brain. We note that our antibodies are
not sensitive enough to detect endogenous levels of Atp7a, so
expression of the transgene at levels equivalent to the normal
protein may not have been visible in the sections. We detected
substantial amounts of ATP7A in the Purkinje cell layer of the
cerebellum, in the CA1 and CA2 region of the hippocampus and
in the mitral layer of olfactory bulb, which are also reported to
express the Atp7a in normal mice [12,34]. This expression of the
transgene may have assisted in the restoration of normal brain
function, however, the complete role of the Menkes protein and
indeed copper in the brain is far from clear.
In Menkes patients copper accumulates in the proximal
tubules of the kidney, the place of copper resorption [11]. We
found ATP7A expression in the macular densa of the distal
tubules, in tubules in the outer cortex, as well as in the thin loops
of Henle in the outer medulla, which was sufficient to reduce the
copper levels of the corrected mutant males compared to the
heterozygote females. Comparison of transgene expression with
the endogenous Atp7a is complicated by the differences in
published reports of the expression pattern of Atp7a in the
kidney. For example, strong endogenous Atp7a expression was
found by in situ hybridization studies in the proximal tubules,
however low levels of expression were found in the glomeruli
[35]. Moore and Cox found strong endogenous expression in
the glomeruli using in situ hybridization and slight expression in
the interior of various tubules [36]. We have previously detected
Atp7a in both the proximal and distal convoluted tubules with
little staining in the glomeruli [8].
Normally the livers of fetal mice accumulate copper far
above the adult levels, and the high concentrations are
maintained throughout the first 10–15 days of life [18]. The
uncorrected mutant has an extremely low hepatic copper
concentration of 10.7±2.4 μg/g at 12 days compared with the
normal male littermate (164.5±70.6 μg/g), consistent with the
severe copper deficiency of the mutants. This low liver copper
is primarily due to the defective transport of copper across the
mutant placenta [7]. The transgene only partially corrects this
deficiency, with the hepatic copper being only 15.8±4.5 μg/g.
This value suggests that the expression of the transgene must be
moderately restricted in the placenta but we have not assessed
placental expression. Interestingly the 12-day-old heterozygous
females have low hepatic copper as well (14.9±3.6 μg/g) whichmay be due to the preferential inactivation of the normal
paternal allele in the placenta leaving most of the fetal placenta
with the mutant X active [37]. The transgene in the
heterozygous females increases hepatic copper concentrations
of around 50 μg/g closer to the normal values than the corrected
mutant males. It is probable that the expression of the transgene
in the placenta supplements the restricted placental copper
transport by increasing the number of placental trophoblasts
expressing an active Menkes protein. Despite the low hepatic
copper concentrations in the corrected mutant males and
heterozygous females the pups develop normally.
In conclusion, the rescue of the brindled mutants demon-
strates that even partial correction of the Menkes genetic defect
in humans would be sufficient for relatively normal develop-
ment and these mice also will provide further information about
the role of the Menkes ATPase in copper physiology.
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